Gadopentetate dimeglumine-enhanced three-dimensional MR-angiography: dosing, safety, and efficacy.
Noninvasiveness, inherent three-dimensionality allowing reformations in any desired plane, and safe contrast agents, coupled with high diagnostic accuracy have driven the rise in popularity of contrast-enhanced MR angiography (CE-MRA) within the medical community. Reflecting its dominant market share as a paramagnetic contrast agent, gadopentetate dimeglumine (Gd-DTPA) has been used for the majority of clinically-performed MRA exams. Over the period January 1994 to February 2002, a total of 172 original studies describing the use of gadolinium-enhanced MRA in more than three human subjects were identified. Of these, 117 described the use of Gd-DTPA as the contrast agent for MRA. A total of 4046 subjects who received Gd-DTPA for MRA are described in these studies. Analysis of these data demonstrate Gd-DTPA to be a safe contrast agent for MRA when applied in a dose ranging from 0.1 to 0.3 mmol/kg of bodyweight. The documented clinical results show Gd-DTPA to be efficacious in the assessment of the arterial system. The effectiveness of Gd-DTPA-enhanced MRA extends beyond the detection, localization, and characterization of arterial disease, and encompasses choice and planning of appropriate therapy, as well as evaluation of therapeutic effectiveness.
Goyen
Mathias
M
Department of Diagnostic and Interventional Radiology, University Hospital Essen, Essen, Germany. mathias.goyen@uni-essen.de
Debatin
Jörg F
JF
D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000175:diagnosis*; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D019786:Gadolinium DTPA / Q000009:adverse effects; D006801:Humans; D021621:Imaging, Three-Dimensional / Q000379:methods*; D018810:Magnetic Resonance Angiography / Q000379:methods*; D008875:Middle Aged
D003287:Contrast Media; D019786:Gadolinium DTPA